Please login to the form below

Not currently logged in
Email:
Password:

basal cell carcinoma

This page shows the latest basal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s latecomer PD-1 gets date for FDA verdict

Sanofi’s latecomer PD-1 gets date for FDA verdict

The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... after basal cell carcinoma (BCC) and the deadliest

Latest news

More from news
Approximately 5 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Abzena's technology is used to humanise and de-immunise antibodies by avoiding CD4+ T-cell epitopes.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Curis looks to MedImmune and Takeda for new hires Curis looks to MedImmune and Takeda for new hires

    Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics